MetaStat

MTST

Electrical Equipment & Parts · Industrials

Price

$0.00

+0.00 (+0.00%)

Market Cap

$5,877

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+284.4% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 1.4M (2014) → 5.4M (2018)

MetaStat, Inc. is a small biotechnology company focused on cancer research. It works on understanding how cancer cells spread from one part of the body to another, a process called metastasis. The company develops tools and technologies aimed at helping researchers and drug developers study this process more effectively.

MetaStat generates little to no product revenue at this stage and operates primarily as a research-stage company. It is based in the United States and, given its near-zero market cap, is considered a micro-cap or nano-cap company with very limited resources. The company's main risk is its heavy reliance on outside funding to continue operations, as its deeply negative operating margin shows it spends far more than it earns, which is common for early-stage biotech firms that have not yet brought a commercial product to market.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+45.2% YoY

YoY Growth Rate

Strong earnings growth

R&D Spend

$1M/ year

↑ Rising (+25% vs prior year)

>1,000% of revenue

1348.2x the sector average (4%)

Investing heavily in future products and technology

Insider Activity

1.6%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~2 months

$316,933 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Heavy R&D investment

MetaStat is putting 5393% of revenue into R&D and that number is rising. That's 1348.2x the sector average.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-100.0%

Shrinking sales (-100.0% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

1.05x

Dangerous — barely covers interest (1.1x)

Interest coverage between 1 and 3. Profits cover interest, but with little room to spare.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial